Parabilis Medicines, Inc. (PBLS)
30.37
+1.84
(+6.45%)
USD |
NASDAQ |
Nov 09, 16:00
29.77
-0.60
(-1.98%)
After-Hours: 20:00
Parabilis Medicines EPS Diluted (Quarterly) : -0.5421 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.5421 |
| March 31, 2026 | -0.5999 |
| Date | Value |
|---|---|
| June 30, 2025 | -0.3643 |
| March 31, 2025 | -0.4072 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -1.355 |
| Oncolytics Biotech, Inc. | -0.0788 |
| Sangamo Therapeutics, Inc. | -0.0796 |
| Sarepta Therapeutics, Inc. | -0.2687 |
| Anixa Biosciences, Inc. | -0.0762 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -52.46M |
| Revenue (Quarterly) | 0.148M |
| Total Expenses (Quarterly) | 52.61M |
| Enterprise Value | 2.678B |
| Gross Profit Margin (Quarterly) | -300.7% |
| Profit Margin (Quarterly) | -35.45K% |
| Earnings Yield | -6.30% |
| Normalized Earnings Yield | -6.197 |